What is the recommended intramuscular methotrexate dosage and titration schedule for adult patients?

Intramuscular Methotrexate Dosing for Rheumatoid Arthritis

For rheumatoid arthritis, intramuscular methotrexate is NOT the preferred initial route—start with oral methotrexate 15 mg weekly, escalate by 5 mg monthly to 25-30 mg weekly, and only switch to subcutaneous (not intramuscular) administration if there is insufficient response at the highest tolerable oral dose. 1111

Initial Dosing Strategy

The evidence-based approach for methotrexate in RA follows this algorithm:

• Start oral: 15 mg once weekly (not 7.5 mg as some older protocols suggest) 1
• Titration schedule: Increase by 5 mg per month 11
• Target dose: 25-30 mg weekly or the highest tolerable dose 11
• Frequency: Once weekly dosing (not twice weekly or every other week) 1

When to Consider Parenteral Administration

Switch to subcutaneous (not intramuscular) methotrexate only after:

• Insufficient response at maximum tolerated oral dose
• The subcutaneous dose should be 15 mg weekly initially, with potential escalation 1

Critical Evidence on Intramuscular vs Other Routes

The systematic review found that intramuscular methotrexate at 15 mg weekly with subsequent dose escalation did NOT result in increased efficacy in longstanding RA patients who had failed 15-20 mg weekly oral methotrexate 1. This is a crucial finding—IM administration is not superior to oral in this context.

The evidence favors subcutaneous over intramuscular when parenteral administration is needed, as subcutaneous 15 mg weekly showed better response compared to oral 15 mg weekly in early RA 11.

Important Caveats

Bioavailability considerations: While parenteral methotrexate has higher bioavailability at increasing doses, simply escalating the oral dose to 25 mg weekly may achieve similar efficacy to switching to parenteral 15 mg 1. Consider increasing oral dose before switching routes.

Toxicity profile: The evidence on parenteral toxicity is inconsistent—one RCT showed more withdrawal due to toxicity with subcutaneous administration, while observational data suggest decreased gastrointestinal side effects with parenteral routes 1.

Dosing Algorithm Summary

1. Week 1: Oral methotrexate 15 mg once weekly
2. Month 2: Increase to 20 mg weekly (if tolerated)
3. Month 3: Increase to 25 mg weekly (if tolerated)
4. Month 4: Increase to 30 mg weekly if needed (maximum tolerable dose)
5. If inadequate response: Switch to subcutaneous 15 mg weekly with further escalation as needed

Do not start with intramuscular methotrexate as first-line therapy. The guideline evidence consistently supports oral initiation with subcutaneous (not intramuscular) as the preferred parenteral alternative 1111.